Abstract #3395
Nasal MOG ameliorates MRI brain pathology in progressive EAE
Hilit Levy-barazany 1 , Daniel Barazany 1,2 , Lindsay Puckett 3 , Shani Kanfi 1 , Nofit Borenstein-Auerbach 1 , Kayong Yang 3 , Jean Pierre S Peron 3 , Howard L Weiner 3 , and Dan Frenkel 1,4
1
Department of Neurobiology, Tel Aviv
Unviersity, Tel Aviv, Israel,
2
CUBRIC
School of Psychology, Cardiff University, Cardiff,
United Kingdom,
3
Department of Neurology,
Center for Neurologic Diseases, Brigham and Women's
Hospital, Harvard Medical School, Boston, MA, United
States,
4
Sagol
School of Neuroscience, Tel Aviv, Israel
MS is an autoimmune disease of the CNS in which
pro-inflammatory processes that target self myelin lead
to demyelination. We have shown that EAE model in
non-obese diabetic mice leads to a chronic disease which
is followed by brain lesion development that can be
monitored by MRI. Here we examined whether immune
responses induced by nasal MOG treatment affect clinical
progression and demyelination in chronic progressive
EAE, and evaluated the effect of the treatment by DTI
and T1-Gd techniques. Our results demonstrate that MRI
can monitor treatment of ongoing disease in this model
for testing new therapies for MS.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
